Weekly Research Analysts’ Ratings Updates for Illumina (ILMN)

A number of firms have modified their ratings and price targets on shares of Illumina (NASDAQ: ILMN) recently:

  • 2/5/2018 – Illumina was upgraded by analysts at Citigroup Inc from a “neutral” rating to a “buy” rating. They now have a $275.00 price target on the stock, up previously from $260.00.
  • 2/3/2018 – Illumina was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/31/2018 – Illumina had its price target raised by analysts at Barclays PLC from $200.00 to $215.00. They now have an “equal weight” rating on the stock.
  • 1/31/2018 – Illumina had its “hold” rating reaffirmed by analysts at Citigroup Inc. They now have a $260.00 price target on the stock.
  • 1/31/2018 – Illumina had its price target raised by analysts at Morgan Stanley from $145.00 to $157.00. They now have an “underweight” rating on the stock.
  • 1/31/2018 – Illumina had its price target raised by analysts at Leerink Swann from $250.00 to $276.00. They now have an “outperform” rating on the stock.
  • 1/31/2018 – Illumina had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $265.00 price target on the stock, up previously from $255.00.
  • 1/31/2018 – Illumina was upgraded by analysts at First Analysis from an “equal weight” rating to an “overweight” rating. They now have a $277.00 price target on the stock.
  • 1/22/2018 – Illumina had its price target raised by analysts at Cowen Inc from $250.00 to $275.00. They now have an “outperform” rating on the stock.
  • 1/16/2018 – Illumina had its “hold” rating reaffirmed by analysts at BTIG Research.
  • 1/16/2018 – Illumina was given a new $275.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 1/9/2018 – Illumina had its “positive” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $260.00 price target on the stock, up previously from $250.00.
  • 1/9/2018 – Illumina had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $269.00 price target on the stock.
  • 1/5/2018 – Illumina was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating.
  • 1/5/2018 – Illumina was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/5/2018 – Illumina is now covered by analysts at BTIG Research. They set a “neutral” rating on the stock.
  • 1/4/2018 – Illumina had its price target raised by analysts at Piper Jaffray Companies to $274.00. They now have an “overweight” rating on the stock.
  • 1/3/2018 – Illumina is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $250.00 price target on the stock.
  • 1/2/2018 – Illumina was upgraded by analysts at Wells Fargo & Co from a “market perform” rating to an “outperform” rating. They now have a $205.00 price target on the stock.
  • 12/26/2017 – Illumina was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Post a promising third-quarter show, we expect Illumina to maintain its growth momentum on continued uptake of sequencing consumables, instruments and microarray portfolios. Management is also hopeful that recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System will drive demand for NovaSeq. We look forward to the launch of NovaSeq Xp workflow. Also, the company’s launch of Nextera DNA Flex buoys optimism. Moreover, the company recently partnered with Telegraph Hill Partners to set up an independent entity. Accordingly, over the last three months, Illumina has been trading above the broader industry. On the flip side, weak margins owing to the NovaSeq launch, higher array services revenues and unfavorable product mix within sequencing consumables will continue to act as deterrents.”
  • 12/14/2017 – Illumina had its price target raised by analysts at Morgan Stanley from $122.00 to $135.00. They now have an “underweight” rating on the stock.

Shares of Illumina, Inc. (ILMN) opened at $217.19 on Monday. The firm has a market capitalization of $31,709.74, a P/E ratio of 43.79, a PEG ratio of 2.87 and a beta of 0.92. Illumina, Inc. has a 52 week low of $158.02 and a 52 week high of $248.97. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.55 and a current ratio of 3.99.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.22. The firm had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The business’s quarterly revenue was up 25.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.85 earnings per share. sell-side analysts forecast that Illumina, Inc. will post 4.59 EPS for the current year.

In related news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $211.35, for a total transaction of $4,227,000.00. Following the completion of the transaction, the director now owns 531,717 shares in the company, valued at $112,378,387.95. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $243.72, for a total value of $3,655,800.00. Following the transaction, the director now owns 449,201 shares of the company’s stock, valued at approximately $109,479,267.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 117,690 shares of company stock valued at $25,989,564. Insiders own 0.89% of the company’s stock.

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply